Expression of HPV16 E6 recombinant protein and preparation of its rabbit polyclonal antibody

0 Comments
medicalpeek

Era of Excessive Affinity Anti-Peptide Polyclonal Antibodies Recognizing Goat α s1-Casein

 

The chemical, technological and allergy properties of goat’s milk are considerably affected by the extent of αs1-casein. Detection and quantification of αs1-casein requires high-specificity strategies to beat high-sequence similarity between this protein and others within the casein household. Unavailability of antibodies with excessive affinity and specificity in direction of goat αs1-casein hinders the event of immuno-based analytical strategies corresponding to enzyme-linked immunosorbent assay (ELISA) and biosensors.

Right here, we report the era of polyclonal antibodies (or immunoglobulins, IgGs) raised in direction of goat αs1-casein N- (Nter) and C-terminal (Cter) peptide sequences. The Nter and Cter peptides of goat αs1-casein have been immunized in rabbits for the era of antisera, which have been purified utilizing protein G affinity chromatography. The binding affinity of the antisera and purified IgGs have been examined and in contrast utilizing oblique ELISA, the place peptide-BSA conjugates and goat αs1-casein have been used because the coating antigens.

The Nter antiserum displayed greater titer than Cter antiserum, at 1/64,000 and 1/32,000 dilutions, respectively. The purification step additional yielded 0.5 mg/mL of purified IgGs from Three mL of antisera. The purified Nter IgG confirmed a considerably (p < 0.05) greater binding affinity in direction of peptide-BSA and goat αs1-casein, with decrease Okd worth at 5.063 × 10-3 μM in comparison with 9.046 × 10-3 μM for the Cter IgG. A cross-reactivity check confirmed that there was no binding in neither Nter nor Cter IgGs in direction of protein extracts from the milk of cow, buffalo, horse and camel. Excessive-quality antibodies generated will permit additional improvement of immuno-based analytical strategies and future in vitro research to be performed on goat αs1-casein.

Expression of HPV16 E6 recombinant protein and preparation of its rabbit polyclonal antibody

 

Goal To specific E6 protein of human papillomavirus (HPV) kind 16 in prokaryotic expression system and put together its polyclonal antibody. Strategies HPV16 E6 gene was obtained from Siha cells by PCR and cloned into pET21a(+) vector to assemble the recombinant plasmid pET21a(+)/HPV16 E6 that was confirmed by sequencing. The recombinant plasmid pET21a(+)/HPV16 E6 was remodeled into E. coli BL21 (DE3).

The HPV16 E6-His tag recombinant protein was expressed after the induction of isopropyl beta-D-1-thiogalactopyranoside (IPTG), purified by Ni-NTA affinity chromatography, after which analyzed by Western blot evaluation. The purified HPV16 E6 recombinant protein was used to immunize Japanese white rabbits to organize polyclonal antibody. The titer of the serum polyclonal antibody was decided by ELISA. The specificity of the polyclonal antibody was analyzed by Western blotting and immunofluorescence.

Outcomes The recombinant plasmid pET21a(+)/HPV16 E6 was efficiently constructed and confirmed by sequencing. After the recombinant plasmid pET21a(+)/HPV16 E6 was remodeled into E. coli BL21 (DE3), the recombinant HPV16 E6 protein was expressed and purified by affinity chromatography.

The polyclonal antibody at a titer of 1:40 000 was obtained by immunizing Japanese big-ear white rabbit with the purified recombinant HPV16 E6 protein, and its specificity was confirmed by Western blotting and immunofluorescence assay. Conclusion HPV16 E6 recombinant protein was efficiently expressed and the rabbit polyclonal antibody in opposition to HPV16 E6 recombinant protein was ready.

Manufacturing of polyclonal antibody in opposition to kidney antigens: a mannequin for finding out autoantibody in feline continual kidney illnesses.

 

  • Continual kidney illness is taken into account to be most typical in geriatric home cats. It has been reported that the feline viral rhinotracheitis, calicivirus, and panleukopenia (FVRCP) vaccine ready from the Crandell-Rees feline kidney (CRFK) cell line can induce cross-reactions of antibodies with feline kidney tissues.
  • As an anti-cat kidney antibody was not accessible commercially for this examine of autoantibody in cats, the aim of this examine was to provide anti-cat kidney antibody in rabbits for additional examine of autoantibody in cats after FVRCP vaccination.

 

  • Kidney proteins from cadaveric cats have been extracted and immunized into rabbits utilizing Montanide because the adjuvant. Based mostly on enzyme-linked immunosorbent assay measurement, all immunized rabbits produced excessive ranges of anti-cat kidney antibodies and a few started to provide antibodies as early as 2 weeks after immunization. Immunofluorescence staining of rabbit sera confirmed kidney-bound antibodies in glomerulus, Bowman’s capsule, apical floor of the proximal convoluted tubule, peritubular floor, and interstitial cells.

 

  • Western blot evaluation of cat kidney proteins revealed molecular weights (M.W.) of 72, 55, 47, and 31 kDa, whereas binding to the CRFK cell proteins was noticed at M.W. of 43 and 26 kDa. The antibody that acknowledged the 47 kDa protein was equally detected in cats with autoantibody presence after FVRCP vaccination. The kidney-bound antibody profile at totally different time factors and its patterns in rabbits may very well be used as a mannequin for the examine of autoantibody to cat kidney in feline continual kidney illnesses.
medicalpeek
medicalpeek

gel casting base 20 cm

EVS1300-BASE ea
EUR 200

gel casting base for evs3100

EVS3100-BASE ea
EUR 301

gel casting base for evs3200

EVS3200-BASE ea
EUR 301

gel casting base for evs3300

EVS3300-BASE ea
EUR 301

Carubicin (Free base)

B1853-1
EUR 153

Carubicin (Free base)

B1853-5
EUR 457

FIPI (free base)

B2372-25
EUR 631

FIPI (free base)

B2372-5
EUR 196

Terbinafine (Free base)

B2423-250
EUR 207

Terbinafine (Free base)

B2423-50
EUR 120

MCC950 (Free base)

B1031-1
EUR 153

MCC950 (Free base)

B1031-5
EUR 457

Apatinib (Free base)

B1613-25
EUR 414

Apatinib (Free base)

B1613-5
EUR 142

AZD4547, Free Base

ADC-P-063 unit Ask for price

AZD8055, Free Base

ADC-P-064 unit Ask for price

Cyclopamine, Free Base

ADC-P-079 unit Ask for price

Ixabepilone, Free Base

ADC-P-104 unit Ask for price

R406(free base)

E1KS1533 2mg
EUR 521

RPR107393 free base

HY-100299 1mg
EUR 481

FR167344 free base

HY-100301 1mg
EUR 2637

FR183998 free base

HY-100302 1mg
EUR 1127

FR194738 free base

HY-100303 1mg
EUR 1990

Vatalanib (free base)

HY-10203 5mg
EUR 119

Masupirdine (free base)

HY-109118 1mg
EUR 223

R406 (free base)

HY-11108 10mM/1mL
EUR 231

ITI214 (free base)

HY-12501 100mg
EUR 2943

AS2863619 (free base)

HY-126675 5mg
EUR 1175

AZD3839 (free base)

HY-13438 50mg
EUR 1014

Ripasudil free base

HY-15685A 10mg
EUR 408

YM158 (free base)

HY-U00355 1mg
EUR 2309

THZ1 (Free base)

9664-25
EUR 1023

THZ1 (Free base)

9664-5
EUR 294

LY2835219 free base

A3575-100 100 mg
EUR 572
Description: LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity.

LY2835219 free base

A3575-25 25 mg
EUR 258
Description: LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity.

LY2835219 free base

A3575-5 5 mg
EUR 142
Description: LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity.

R406 (free base)

A5880-100 100 mg
EUR 1210
Description: R406 is a potent SYK inhibitorSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase mainly expressed in hematopoietic cells. It transmits signals from a variety of cell surface receptors including CD74, Fc receptor and integrins.

R406 (free base)

A5880-25 25 mg
EUR 514
Description: R406 is a potent SYK inhibitorSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase mainly expressed in hematopoietic cells. It transmits signals from a variety of cell surface receptors including CD74, Fc receptor and integrins.

R406 (free base)

A5880-5 5 mg
EUR 166
Description: R406 is a potent SYK inhibitorSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase mainly expressed in hematopoietic cells. It transmits signals from a variety of cell surface receptors including CD74, Fc receptor and integrins.

R406 (free base)

A5880-5.1 10 mM (in 1mL DMSO)
EUR 264
Description: R406 is a potent SYK inhibitorSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase mainly expressed in hematopoietic cells. It transmits signals from a variety of cell surface receptors including CD74, Fc receptor and integrins.

R406 (free base)

A5880-S Evaluation Sample
EUR 81
Description: R406 is a potent SYK inhibitorSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase mainly expressed in hematopoietic cells. It transmits signals from a variety of cell surface receptors including CD74, Fc receptor and integrins.

Rucaparib (free base)

A8893-10 10 mg
EUR 200
Description: Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a key signaling role in the base excision repair pathway.

Rucaparib (free base)

A8893-200 200 mg
EUR 1036
Description: Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a key signaling role in the base excision repair pathway.

Rucaparib (free base)

A8893-5 5 mg
EUR 137
Description: Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a key signaling role in the base excision repair pathway.

Rucaparib (free base)

A8893-5.1 10 mM (in 1mL DMSO)
EUR 142
Description: Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a key signaling role in the base excision repair pathway.

Rucaparib (free base)

A8893-50 50 mg
EUR 456
Description: Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a key signaling role in the base excision repair pathway.

Lapatinib, Free base

2138-100
EUR 387

Lapatinib, Free base

2138-25
EUR 191

Ruxolitinib, Free base

2139-100 Ask for price

Ruxolitinib, Free base

2139-25
EUR 533

Ruxolitinib, Free base

2139-5
EUR 207

Imatinib, Free base

2141-100
EUR 147

Imatinib, Free base

2141-1000
EUR 419

Linsitinib, Free base

2294-25
EUR 566

Linsitinib, Free base

2294-5
EUR 185

Tipifarnib, Free base

2296-1
EUR 142

Tipifarnib, Free base

2296-5
EUR 414

Vatalanib, Free Base

2026-25
EUR 305

Vatalanib, Free Base

2026-5
EUR 126

Erlotinib, Free Base

2048-100
EUR 158

Erlotinib, Free Base

2048-1000
EUR 387

Sunitinib, Free base

2097-100
EUR 191

Sunitinib, Free base

2097-1000
EUR 501

Sunitinib, Free base

2097-25
EUR 115

Xylazine (free base)

Q-1445.0025 25.0g
EUR 321
Description: Sum Formula: C12H16N2S; CAS# [7361-61-7]

PLX5622 (free base)

B2965-25 25 mg
EUR 753

PLX5622 (free base)

B2965-5 5 mg
EUR 227

TMB free base

TB0954 1g
EUR 70.88
  • Product category: Biochemicals/Indicators/Stains/Immuno Related

BMS-345541 (Free base)

B1907-1
EUR 142

BMS-345541 (Free base)

B1907-5
EUR 414

UNC-926, free base

B2158-25
EUR 631

UNC-926, free base

B2158-5
EUR 196

SB-334867 free base

B3423-100 100 mg
EUR 599
Description: SB-334867 free base is a selective antagonist of orexin-1 receptor [1].Orexin-A and orexin-B are two peptides isolated from rat hypothalamus. They are involved in some physiological functions such as the control of feeding, energy metabolism and regulation of the sleep-wake cycle.

SB-334867 free base

B3423-25 25 mg
EUR 290
Description: SB-334867 free base is a selective antagonist of orexin-1 receptor [1].Orexin-A and orexin-B are two peptides isolated from rat hypothalamus. They are involved in some physiological functions such as the control of feeding, energy metabolism and regulation of the sleep-wake cycle.

SB-334867 free base

B3423-5 5 mg
EUR 128
Description: SB-334867 free base is a selective antagonist of orexin-1 receptor [1].Orexin-A and orexin-B are two peptides isolated from rat hypothalamus. They are involved in some physiological functions such as the control of feeding, energy metabolism and regulation of the sleep-wake cycle.

SB-334867 free base

B3423-5.1 10 mM (in 1mL DMSO)
EUR 131
Description: SB-334867 free base is a selective antagonist of orexin-1 receptor [1].Orexin-A and orexin-B are two peptides isolated from rat hypothalamus. They are involved in some physiological functions such as the control of feeding, energy metabolism and regulation of the sleep-wake cycle.

GSK J4 free base

B5959-10 10 mg
EUR 373
Description: GSK J4 free base

GSK J4 free base

B5959-50 50 mg
EUR 1198
Description: GSK J4 free base

BMS-345541(free base)

B4655-10 10 mg
EUR 235
Description: BMS-345541(free base) is a selective inhibitor of IKK-1 and IKK-2 with IC50 value of 4?M and 0.3?M, respectively [1].IKK is also known as nuclear factor kappa-B kinase subunit inhibitor and involves in cytokine-activated intracellular signaling pathways.

BMS-345541(free base)

B4655-5 5 mg
EUR 171
Description: BMS-345541(free base) is a selective inhibitor of IKK-1 and IKK-2 with IC50 value of 4?M and 0.3?M, respectively [1].IKK is also known as nuclear factor kappa-B kinase subunit inhibitor and involves in cytokine-activated intracellular signaling pathways.

BMS-345541(free base)

B4655-50 50 mg
EUR 595
Description: BMS-345541(free base) is a selective inhibitor of IKK-1 and IKK-2 with IC50 value of 4?M and 0.3?M, respectively [1].IKK is also known as nuclear factor kappa-B kinase subunit inhibitor and involves in cytokine-activated intracellular signaling pathways.

Staurosporine, >99% Free Base

BC090-001 1mg
EUR 246

Staurosporine, >99% Free Base

BC090-005 5mg
EUR 340

Vandetanib, >99% Free Base

BC098-025 25mg
EUR 232

Vandetanib, >99% Free Base

BC098-050 50mg
EUR 286

Vandetanib, >99% Free Base

BC098-100 100mg
EUR 313

Vandetanib, >100% Free Base

BC098-500 500mg
EUR 658

FK-448 Free base

HY-100193 10mg
EUR 1887

KW-8232 free base

HY-100304 10mg
EUR 5018

YM-53601 free base

HY-100313 1mg
EUR 1559

AV-412 (free base)

HY-10346A 5mg
EUR 173

SB-334867 (free base)

HY-10895A 10mg
EUR 215

SNT-207858 (free base)

HY-11030A 10mg
EUR 911

DOV-216,303 (Free Base)

HY-18332C 10mM/1mL
EUR 492

APX-115 (free base)

HY-120801A 5mg
EUR 223

LY-2584702 (free base)

HY-12493 5mg
EUR 165

Genz-123346 (free base)

HY-12744 10mM/1mL
EUR 189

YHO-13351 (free base)

HY-12758A 10mM/1mL
EUR 176

JTV-519 (free base)

HY-15293A 5mg
EUR 567

RGB-286638 (free base)

HY-15504A 100mg
EUR 2804

CP-319340(free base)

HY-U00270 5mg
EUR 877

SGI-1776 free base

A4192-10 10 mg
EUR 247
Description: SGI-1776 free base, N-((1-methylpiperidin-4-yl)methyl)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-amine, is a potent ATP-competitive inhibitor of the serine/threonine family of Pim kinase, an enzyme regulating cell survival.

SGI-1776 free base

A4192-5 5 mg
EUR 154
Description: SGI-1776 free base, N-((1-methylpiperidin-4-yl)methyl)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-amine, is a potent ATP-competitive inhibitor of the serine/threonine family of Pim kinase, an enzyme regulating cell survival.

SGI-1776 free base

A4192-5.1 10 mM (in 1mL DMSO)
EUR 166
Description: SGI-1776 free base, N-((1-methylpiperidin-4-yl)methyl)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-amine, is a potent ATP-competitive inhibitor of the serine/threonine family of Pim kinase, an enzyme regulating cell survival.

SGI-1776 free base

A4192-50 50 mg
EUR 525
Description: SGI-1776 free base, N-((1-methylpiperidin-4-yl)methyl)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-amine, is a potent ATP-competitive inhibitor of the serine/threonine family of Pim kinase, an enzyme regulating cell survival.

SGI-1776 free base

A4192-S Evaluation Sample
EUR 81
Description: SGI-1776 free base, N-((1-methylpiperidin-4-yl)methyl)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-amine, is a potent ATP-competitive inhibitor of the serine/threonine family of Pim kinase, an enzyme regulating cell survival.

AM-095 free base

A3167-10 10 mg
EUR 212
Description: AM095 is a novel, potent and orally bioavailable antagonist of lysophosphatidic acid type 1 receptor (LPA1) with IC50 values of 0.73 and 0.98 ?M for mouse or recombinant human LPA1, respectively [1].

AM-095 free base

A3167-100 100 mg
EUR 804
Description: AM095 is a novel, potent and orally bioavailable antagonist of lysophosphatidic acid type 1 receptor (LPA1) with IC50 values of 0.73 and 0.98 ?M for mouse or recombinant human LPA1, respectively [1].

AM-095 free base

A3167-200 200 mg
EUR 1152
Description: AM095 is a novel, potent and orally bioavailable antagonist of lysophosphatidic acid type 1 receptor (LPA1) with IC50 values of 0.73 and 0.98 ?M for mouse or recombinant human LPA1, respectively [1].

AM-095 free base

A3167-5 5 mg
EUR 166
Description: AM095 is a novel, potent and orally bioavailable antagonist of lysophosphatidic acid type 1 receptor (LPA1) with IC50 values of 0.73 and 0.98 ?M for mouse or recombinant human LPA1, respectively [1].

AM-095 free base

A3167-50 50 mg
EUR 572
Description: AM095 is a novel, potent and orally bioavailable antagonist of lysophosphatidic acid type 1 receptor (LPA1) with IC50 values of 0.73 and 0.98 ?M for mouse or recombinant human LPA1, respectively [1].

RGB-286638,  free base

2886-25
EUR 756

RGB-286638,  free base

2886-5
EUR 229

StemRegenin 1, Free base

2642-1
EUR 131

StemRegenin 1, Free base

2642-5
EUR 332

GSK-J4 (Free base)

2762-1
EUR 120

GSK-J4 (Free base)

2762-5
EUR 262

Z-NHNH2 (free base)

Q-1150.0025 25.0g
EUR 126
Description: Sum Formula: C8H10N2O2; CAS# [5331-43-1]

Z-NHNH2 (free base)

Q-1150.0100 100.0g
EUR 321
Description: Sum Formula: C8H10N2O2; CAS# [5331-43-1]

L-Arginine free base

AB0205 100g
EUR 63.15
  • Product category: Biochemicals/Amino Acids/Derivatives

Afatinib

HY-10261 200mg
EUR 312

Afatinib

A170-100MG 100mg
EUR 102

SB 202190, >99% Free Base

BC086-025 25mg
EUR 205

SB 202190, >99% Free Base

BC086-050 50mg
EUR 246

SB 203580, >99% Free Base

BC087-025 25mg
EUR 219

SB 203580, >99% Free Base

BC087-050 50mg
EUR 286

Gastrofensin AN 5 free base

HY-100296 5mg
EUR 2120

Bay 65-1942 (free base)

HY-50949 10mg
EUR 1069

Glyoxalase I inhibitor (free base)

HY-15167A 50mg
EUR 2530

Biotin ethylenediamine (free base form)

90071 25MG
EUR 132
Description: Minimum order quantity: 1 unit of 25MG

biotin cadaverine, free base form

90079 50MG
EUR 215
Description: Minimum order quantity: 1 unit of 50MG

BAY 43-9006, Free base

2142-100
EUR 419

BAY 43-9006, Free base

2142-25
EUR 169

BAY 58-2667 (Free base)

2452-1
EUR 354

BAY 58-2667 (Free base)

2452-5
EUR 1132

EZSolution? StemRegenin 1, Free base

2643-1
EUR 142

H-Tyr-OEt (free base)

E-2900.0025 25.0g
EUR 139
Description: Sum Formula: C11H15NO3; CAS# [949-67-7]

H-Tyr-OEt (free base)

E-2900.0100 100.0g
EUR 357
Description: Sum Formula: C11H15NO3; CAS# [949-67-7]

Afatinib (dimaleate)

HY-10261A 200mg
EUR 312

Afatinib dimaleate

A3145-10 10 mg
EUR 221
Description: Afatinib is an irreversible EGFR/HER2 inhibitor with an IC50 of 14 nM for in vitro potency against HER2.

Afatinib dimaleate

A3145-5 5 mg
EUR 147
Description: Afatinib is an irreversible EGFR/HER2 inhibitor with an IC50 of 14 nM for in vitro potency against HER2.

Afatinib dimaleate

A3145-5.1 10 mM (in 1mL DMSO)
EUR 119
Description: Afatinib is an irreversible EGFR/HER2 inhibitor with an IC50 of 14 nM for in vitro potency against HER2.

Afatinib dimaleate

A3145-50 50 mg
EUR 512
Description: Afatinib is an irreversible EGFR/HER2 inhibitor with an IC50 of 14 nM for in vitro potency against HER2.

Afatinib (BIBW2992)

A8247-10 10 mg
EUR 221
Description: Afatinib (BIBW2992), an irreversible inhibitor of the ErbB family of tyrosine kinases, downregulates ErbB signalling by binding to the kinase domains of epidermal growth factor receptor (EGFR)/ human epidermal growth factor receptor 2 (HER2) with IC50 of 0.5 nM and 14nM, respectively.

Afatinib (BIBW2992)

A8247-5 5 mg
EUR 147
Description: Afatinib (BIBW2992), an irreversible inhibitor of the ErbB family of tyrosine kinases, downregulates ErbB signalling by binding to the kinase domains of epidermal growth factor receptor (EGFR)/ human epidermal growth factor receptor 2 (HER2) with IC50 of 0.5 nM and 14nM, respectively.

Afatinib (BIBW2992)

A8247-5.1 10 mM (in 1mL DMSO)
EUR 244
Description: Afatinib (BIBW2992), an irreversible inhibitor of the ErbB family of tyrosine kinases, downregulates ErbB signalling by binding to the kinase domains of epidermal growth factor receptor (EGFR)/ human epidermal growth factor receptor 2 (HER2) with IC50 of 0.5 nM and 14nM, respectively.

Afatinib (BIBW2992)

A8247-50 50 mg
EUR 512
Description: Afatinib (BIBW2992), an irreversible inhibitor of the ErbB family of tyrosine kinases, downregulates ErbB signalling by binding to the kinase domains of epidermal growth factor receptor (EGFR)/ human epidermal growth factor receptor 2 (HER2) with IC50 of 0.5 nM and 14nM, respectively.

Afatinib (BIBW2992)

A8247-S Evaluation Sample
EUR 81
Description: Afatinib (BIBW2992), an irreversible inhibitor of the ErbB family of tyrosine kinases, downregulates ErbB signalling by binding to the kinase domains of epidermal growth factor receptor (EGFR)/ human epidermal growth factor receptor 2 (HER2) with IC50 of 0.5 nM and 14nM, respectively.

Human Free PSA (f-PSA) ELISA Kit

PRB-5049-FREE 96 assays
EUR 572

PNU-282987 (S enantiomer free base)

HY-12560D 5mg
EUR 1014

Cyclosporin A-Derivative 1 (Free base)

HY-P1355A 1mg
EUR 223

biotin-x cadaverine, free base form

90080 20MG
EUR 215
Description: Minimum order quantity: 1 unit of 20MG

H-Arg(Mtr)-OtBu (free base)

E-3075.0001 1.0g
EUR 309
Description: Sum Formula: C20H34N4O5S; CAS# [115608-61-2]

H-Arg(Mtr)-OtBu (free base)

E-3075.0005 5.0g
EUR 1143
Description: Sum Formula: C20H34N4O5S; CAS# [115608-61-2]

H-Arg(Pmc)-OtBu (free base)

E-3085.0001 1.0g
EUR 418
Description: Sum Formula: C24H40N4O5S; CAS# [169543-81-1]

H-Arg(Pmc)-OtBu (free base)

E-3085.0005 5.0g
EUR 1554
Description: Sum Formula: C24H40N4O5S; CAS# [169543-81-1]

CHIR 99021, GSK-3 Inhibitor , Free Base

BC212-002 2 mg
EUR 178

CHIR 99021, GSK-3 Inhibitor , Free Base

BC212-005 5 mg
EUR 265

CHIR 99021, GSK-3 Inhibitor , Free Base

BC212-010 10 mg
EUR 315

CHIR 99021, GSK-3 Inhibitor , Free Base

BC212-025 25 mg
EUR 394

CHIR 99021, GSK-3 Inhibitor , Free Base

BC212-100 100 mg
EUR 887

H-Ala-Ala-Phe-AMC (free base)

I-1415.0050 50.0mg
EUR 151
Description: Sum Formula: C25H28N4O5; CAS# [62037-41-6]

H-Ala-Ala-Phe-AMC (free base)

I-1415.0250 250.0mg
EUR 515
Description: Sum Formula: C25H28N4O5; CAS# [62037-41-6]

Human Free PSA (f-PSA) ELISA Kit

PRB-5049-FREE-5 5 x 96 assays
EUR 2283

(D-Ser(tBu)6,Azagly10)-LHRH (free base)

H-7296.0005 5.0mg
EUR 183
Description: Sum Formula: C59H84N18O14; CAS# [65807-02-5]

(D-Ser(tBu)6,Azagly10)-LHRH (free base)

H-7296.0025 25.0mg
EUR 641
Description: Sum Formula: C59H84N18O14; CAS# [65807-02-5]

casting base

EHS3100-CAST ea
EUR 107

casting base

EHS3200-CAST ea
EUR 124

casting base

EHS3300-CAST ea
EUR 124

Rimonabant base

GX9120-10MG 10 mg
EUR 86

Rimonabant base

GX9120-25MG 25 mg
EUR 130

Tetracycline base

GA9779-100G 100 g
EUR 150

Tetracycline base

GA9779-10G 10 g
EUR 46

Tetracycline base

GA9779-25G 25 g
EUR 62

Tris-base

20-abx082498
  • EUR 328.00
  • EUR 203.00
  • EUR 411.00
  • 1 kg
  • 500 g
  • 5 kg
  • Shipped within 5-10 working days.

ProteoIQ Base

PS2 1
EUR 4262

Vincamine base

Q-1435.0005 5.0g
EUR 225
Description: Sum Formula: C21H26N2O3; CAS# [1617-90-9]

Vincamine base

Q-1435.0025 25.0g
EUR 803
Description: Sum Formula: C21H26N2O3; CAS# [1617-90-9]

CETRIMIDE AGAR BASE

C03-107-10kg 10 kg
EUR 1229

CETRIMIDE AGAR BASE

C03-107-2Kg 2 Kg
EUR 306

CETRIMIDE AGAR BASE

C03-107-500g 500 g
EUR 120

Fuchsine base (monohydrochloride)

HY-B1539A 1g
EUR 119

Rhodamine B base

GT5360-100G 100 g
EUR 158

Rhodamine B base

GT5360-10G 10 g
EUR 50

Rhodamine B base

GT5360-25G 25 g
EUR 70

Rhodamine B base

GT5360-50G 50 g
EUR 102

Preparation and software of mouse polyclonal antibodies in opposition to human Shisa like 1 (SSL1)

 

Goal: To organize polyclonal antibodies in opposition to Shisa like 1 protein (SSL1) and examine the localization of SSL1 in hepatocellular carcinoma SMMC-7721 cells.

Strategies: Human SSL1 gene was cloned from HepG2 cells by reverse transcription PCR, after which inserted into prokaryotic expression vector pET-28a to generate the SSL1 expression vector. The recombinant plasmid pET28a-SSL1 was then remodeled into E. coli BL21 (DE3) and induced to specific by IPTG.

Polyclonal antibody in opposition to SSL1 was generated by immunizing Kunming mouse with the purified protein by the routine methodology. The specificity of polyclonal antibody was verified by Western blot evaluation. The expression of SSL1 in SMMC-7721 cells was detected by immunofluorescent cytochemistry. Golgi complexes have been signed by Golgi-Tracker Purple to investigate the subcellular localization of SSL1 protein in SMMC-7721 cells.

 

Outcomes The SSL1 gene was cloned and the recombinant vector pET28a-SSL1 was efficiently constructed. Pure SSL1 protein expression in E. coli BL21 was confirmed and polyclonal antibodies in opposition to protein SSL1 was obtained in immunized Kunming mice. Immunofluorescent cytochemistry confirmed that SSL1 was expressed within the cytoplasm, and was co-localized with Golgi-Tracker Purple in SMMC-7721 cells. Conclusion We’ve obtained SSL1 polyclonal antibodies with excessive specificity, which was proved located in Golgi our bodies of SMMC-7721 cells.

 

Improvement and characterization of polyclonal antibody in opposition to human kappa gentle chain in rabbit.

 

Polyclonal antibodies in opposition to kappa gentle chain are used to diagnose illnesses producing free gentle chain. The kappa and lambda gentle chains are merchandise of immunoglobulin synthesis and launched into the circulation in minor amounts corresponding to serum, cerebrospinal fluid, urine and synovial fluid in regular situation. The aim of this examine was the manufacturing and purification of polyclonal immunoglobulin G (IgG) in opposition to human kappa gentle chains.

On this examine, early human IgG was purified by ion-exchange chromatography, diminished with Dithiothreitol and heavy and lightweight chains have been separated with size-exclusion chromatography. Afterward, affinity chromatography with protein L Sepharose at pH 2.00 was exhibited to be a dominant situation for the separation and purification of the kappa gentle chain of immunoglobulins from human serum. Finally, the rabbit was immunized by human kappa gentle chains.

The rabbit IgG was purified and labeled with horseradish peroxidase (HRP). Direct enzyme-linked immunosorbent assay was deliberate to find out the titer of HRP conjugated rabbit IgG in opposition to the human kappa gentle chain. The optimum titer of anti-kappa IgG was 1:16000. On the end result, purified polyclonal anti-kappa is great tool in biomedical and biochemical researches and diagnostic kits.

Leave a Reply

Your email address will not be published. Required fields are marked *